---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-089981"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:45:08.706944+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Tivic Health amends Statera license; may pay royalties in securities, directs up to $5.6M to Avenue Capital

## Summary
- Amended license agreement gives Tivic discretion to pay future royalties in cash or its own securities.
- Subsequent payments to Statera, up to $5.6M aggregate, will be paid directly to Avenue Capital on Statera's behalf.
- Original exclusive license for Entolimod (TLR5 agonist) for Acute Radiation Syndrome and option for other indications unchanged.
- License fee of $300K cash plus 945,785 common shares and convertible preferred shares already paid at closing in Feb 2025.

## SEC filing metadata
- accession: 0000950170-25-089981
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025089981/0000950170-25-089981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025089981/tivc-20250618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-089981
- JSON: https://secwatch.observer/filing/0000950170-25-089981.json
- Plain text: https://secwatch.observer/filing/0000950170-25-089981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.